Lifesci Capital Begins Coverage on Eloxx Pharmaceuticals (NASDAQ:ELOX)

Stock analysts at Lifesci Capital started coverage on shares of Eloxx Pharmaceuticals (NASDAQ:ELOX) in a report issued on Wednesday,Benzinga reports. The brokerage set an “outperform” rating and a $40.00 price target on the stock. Lifesci Capital’s price target would indicate a potential upside of 239.27% from the stock’s current price.

Separately, Guggenheim began coverage on Eloxx Pharmaceuticals in a research note on Monday. They issued a “buy” rating and a $43.00 target price for the company. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $41.50.

Eloxx Pharmaceuticals Price Performance

Shares of NASDAQ:ELOX traded down $0.21 during trading on Wednesday, reaching $11.79. 237,015 shares of the company’s stock traded hands, compared to its average volume of 25,218. The stock has a market cap of $8.14 million, a PE ratio of -0.77 and a beta of -1,891.27. Eloxx Pharmaceuticals has a 12 month low of $11.42 and a 12 month high of $17.50. The company’s 50 day moving average is $17.32.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.